

Human IL-17A ELISA Kit

Instructions for use

Catalogue numbers:

1x48 tests: EA101262 1x96 tests: EA101263 2x96 tests: EA101264

For research use only

Fast Track Your Research.....

Table of Contents

1.	Intended use	3
2.	Introduction	3
2.1.	Summary	3
2.2.	Principle of the method	3
3.	Reagents provided and reconstitution	4
4.	Materials required but not provided	4
5.	Storage Instructions	4
6.	Specimen collection, processing & storage	5
7.	Safety & precautions for use	6
8.	Assay Preparation	7
8.1.	Assay Design	7
8.2.	Preparation of Wash Buffer	7
8.3.	Preparation of Standard Diluent Buffer	7
8.4.	Preparation of Standard	8
8.5.	Preparation of Samples	8
8.6.	Preparation of Biotinylated anti-IL-17A	8
8.7.	Preparation of Streptavidin-HRP	9
9.	Method1	0
10.	Data Analysis1	1
11.	Assay limitations1	1
12.	Performance Characteristics1	2
12.1	. Sensitivity1	2
12.2	. Specificity1	2
12.3	Precision1	2
12.4	Dilution Parallelism1	3
12.5	Spike Recovery1	3
12.6	. Stability1	3
12.7	. Expected serum values1	3
12.8	Standard Calibration1	3
13.	Bibliography1	4
14.	OriGenelL-17A ELISA references1	4
15.	Assay Summary1	5
12.4 12.5 12.6 12.7 12.8 13. 14.	Dilution Parallelism	3 3 3 4

Human IL-17A ELISA KIT

1. Intended use

The OriGene IL-17A ELISA kit is a solid phase sandwich ELISA for the *in vitro* qualitative and quantitative determination of IL-17A in supernatants, buffered solutions or serum and plasma samples and other body fluids. This assay will recognise both natural and recombinant human IL-17A.

This kit has been configured for research use only.

2. Introduction

2.1. Summary

Interleukin-17 (IL-17, or IL-17A) is the founding member of a group of cytokines called the IL-17 family. IL-17A, was originally identified as a transcript from a rodent T-cell hybridoma by Rouvier et al. in 1993. IL-17A is involved in inducing and mediating proinflammatory responses, commonly associated with allergic responses and induces the production of many other cytokines (such as IL-6, G-CSF, GM-CSF, IL-1 β , TGF- β , TNF- α), chemokines (including IL-8, GRO- α and MCP-1) and prostaglandins (e.g. PGE₂) from many cell types (fibroblasts, endothelial cells, epithelial cells, keratinocytes and macrophages). IL-17A function is also essential to a subset of CD4+ T-Cells called T helper 17 (T_h17) cells.

2.2. Principle of the method

A capture Antibody highly specific for IL-17A has been coated to the wells of the microtitre strip plate provided during manufacture. Binding of IL-17A in samples and known standards to the capture antibodies is completed and then any excess unbound analyte is removed. During the next incubation period the binding of the biotinylated anti-IL-17A secondary antibody to the analyte occurs. Any excess unbound secondary antibody is then removed. The HRP conjugate solution is then added to every well including the zero wells, following incubation excess conjugate is removed by careful washing. A chromogen substrate is added to the wells resulting in the progressive development of a blue coloured complex with the conjugate. The colour development is then stopped by the addition of acid turning the resultant final product yellow. The intensity of the produced coloured complex is directly proportional to the concentration of IL-17A present in the samples and standards. The absorbance of the colour complex is then measured and the generated OD values for each standard are plotted against expected concentration of IL-17A in any sample tested.

3. Reagents provided and reconstitution

Reagents (Store@2-8°C)	Quantity 1x48 well kit Cat no. EA101262	Quantity 1x96 well kit Cat no. EA101263	Quantity 2x96 well kit Cat no. EA101264	Reconstitution
96 well microtitre strip plate	1/2	1	2	Ready to use (Pre-coated)
Plastic plate covers	2	2	4	n/a
Standard: 100pg/ml	1	2	4	Reconstitute as directed on the vial (see Assay preparation, section 8)
Standard Diluent (Buffer)	1 (25ml)	1 (25ml)	1 (25ml)	10x Concentrate, dilute in distilled water (see reagent preparation, section 8)
Biotinylated anti-IL-17A	1 (0.4ml)	1 (0.4ml)	2 (0.4ml)	Dilute in biotinylated antibody diluent (see Assay preparation, section 8)
Biotinylated Antibody diluent	1 (7ml)	1 (7ml)	1 (13ml)	Ready to use
Streptavidin-HRP	1 (5µl)	2 (5µl)	4 (5µl)	Add 0.5ml of HRP diluent prior to use (see Assay preparation, section 8)
HRP Diluent	1 (23ml)	1 (23ml)	1 (23ml)	Ready to use
Wash Buffer 1 (10ml) 1 (10ml		1 (10ml)	2 (10ml)	200x Concentrate dilute in distilled water (see Assay preparation, section 8)
TMB Substrate	1 (11ml)	1 (11ml)	1 (24ml)	Ready to use
H ₂ SO ₄ stop reagent	1 (11ml)	1 (11ml)	2 (11ml)	Ready to use

4. Materials required but not provided

- Microtitre plate reader fitted with appropriate filters (450nm required with optional 620nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and 1,000µl adjustable single channel micropipettes with disposable tips
- 50-300µl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

5. Storage Instructions

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

Wash Buffer: Once prepared store at 2-8°C for up to 1 week Standard Diluent Buffer: Once prepared store at 2-8°C for up to 1 week Standards and Controls: Once prepared use immediately and do not store Biotinylated Secondary Antibody: Once prepared use immediately and do not store Streptavidin-HRP: Once prepared use immediately and do not store

6. Specimen collection, processing& storage

Cell culture supernatants, human serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

Cell culture supernatants: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum: Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. Following clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma: EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

Storage: If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid repeated freeze-thaw cycles and stored frozen at –70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

Recommendation: Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

7. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures , e.g.CDC/NIH Health manual : " Biosafety in Microbiological and Biomedical Laboratories" 1984
- The human serum included in this kit have been tested and found non reactive for HbsAg, anti HIV1 & 2 and anti VHC. Nevertheless, no known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore handling of reagents, serum or plasma specimens should be in accordance with local safety procedures
- Laboratory gloves should be worn at all times
- Avoid any skin contact with H₂SO₄ and TMB. In case of contact, wash thoroughly with water
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration
- Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H₂SO₄ and substrate solution, avoid pipettes with metal parts
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbance's within 1 hour after completion of the assay
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- Follow incubation times described in the assay procedure
- Dispense the TMB solution within 15 min of the washing of the microtitre plate

8. Assay Preparation

Bring all reagents to room temperature before use

8.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and zero should be tested **in duplicate**. Remove sufficient Microwell Strips for testing from the aluminium pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

	Stand	dards	Sample Wells									
	1	2	3	4	5	6	7	8	9	10	11	12
Α	100	100										
В	50	50										
С	25	25										
D	12.5	12.5										
E	6.25	6.25										
F	3.125	3.125										
G	zero	zero										
Н												

All remaining empty wells can be used to test samples in duplicate

8.2. Preparation of Wash Buffer

Dilute the (200x) wash buffer concentrate 200 fold with distilled water to give a 1x working solution. Pour entire contents (10 ml) of the Washing Buffer Concentrate into a clean 2,000 ml graduated cylinder.Bring final volume to 2,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store at 2° - 8° C for up to 1 week.

8.3. Preparation of Standard Diluent Buffer

Add the contents of the vial (10x concentrate) to 225ml of distilled water before use.

This solution can be stored at 2-8°C for up to 1 week.

8.4. Preparation of Standard

Standard vials must be reconstituted with the volume of standard diluent shown on the vial immediately prior to use. This reconstitution gives a stock solution of 100pg/ml of IL-17A. **Mix the reconstituted standard gently by inversion only**. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 100 to 3.125pg/ml. A fresh standard curve should be produced for each new assay.

- Immediately after reconstitution add 200µl of the reconstituted standard to well's A1 and A2, which
 provides the highest concentration standard at 100pg/ml
- Add 100µl of appropriate standard diluent to the remaining standard wells B1 and B2 to F1 and F2
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Continue this 1:1 dilution using 100μl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 100pg/ml to 3.125pg/ml
- Discard 100µl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred directly into the relevant wells.

8.5. Preparation of Samples

Before testing, human serum or plasmas samples have to be diluted 1:2 in standard buffer diluent.

8.6. Preparation of Biotinylated anti-IL-17A

It is recommended this reagent is prepared immediately before use. Dilute the biotinylated anti-IL-17A with the biotinylated antibody diluent in an appropriate clean glass vial using volumes appropriate to the number of required wells. Please see example volumes below:

Number of wells	Biotinylated	Biotinylated		
required	Antibody (µl)	Antibody Diluent (µl)		
16	40	1060		
24	60	1590		
32	80	2120		
48	120	3180		
96	240	6360		

8.7. Preparation of Streptavidin-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom.

Dilute the 5μ l vial with 0.5ml of HRP diluent **immediately before use.** Do-not keep this diluted vial for future experiments. Further dilute the HRP solution to volumes appropriate for the number of required wells in a clean glass vial. Please see example volumes below:

Number of wells	Streptavidin-HRP	Streptavidin-HRP
required	(μl)	Diluent (ml)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10

9. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use except the standard vial which must be mixed gently by inversion only.

Prepare all reagents as shown in section 8.

Note: Final preparation of Biotinylated anti-IL-17A (section 8.5) and Streptavidin-HRP (section 8.6) should occur immediately before use.

As	say Step	Details				
1.	Addition	Prepare Standard curve as shown in section 8.4				
2.	Addition	Add 100μ l of each, Sample and zero (appropriate standard diluent) in duplicate to appropriate number of wells				
3.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 2 hour(s)				
4.	Wash	 Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x washing solution into each well c) Aspirate the contents of each well d) Repeat step b and c another two times 				
5.	Addition	Add 50µl of diluted biotinylated anti-IL-17A to all wells				
6.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hour(s)				
7.	Wash	Repeat wash step 4.				
8.	Addition	Add 100µl of Streptavidin-HRP solution into all wells				
9.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 30 min				
10.	Wash	Repeat wash step 4.				
11.	Addition	Add 100µl of ready-to-use TMB Substrate Solution into all wells				
12.	Incubation	Incubate in the dark for 5-15 minutes * at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil.				
13.	Addition	Add 100µl of H₂SO₄:Stop Reagent into all wells				
450 i	Read the absorbance value of each well (immediately after step 13.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 620 nm as the reference wave length (610 nm to 650 nm in acceptable)					

nm is acceptable).

*Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range

10. Data Analysis


Calculate the average absorbance values for each set of duplicate standards and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding IL-17A standard concentration on the horizontal axis.

The amount of IL-17A in each sample is determined by extrapolating OD values against IL-17A standard concentrations using the standard curve.

Standard	IL-17A Conc	OD (450nm) mean	CV (%)
1	100	1.750	6.9
2	50	0.969	1.5
3	25	0.539	1.9
4	12.5	0.308	3.2
5	6.25	0.179	4.3
6	3.125	0.126	0.3
Zero	0	0.063	4.9

Example IL-17A Standard curve



Note; curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

For samples human serum or plasmas which have been diluted 1:2 according to the protocol, the calculated concentration should be multiplied by the dilution factor (x2)

11. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore **afresh standard curve must be prepared and run for every assay.**

12. Performance Characteristics

12.1. Sensitivity

The sensitivity, minimum detectable dose of IL-17A using this OriGenelL-17A ELISA kit was found to be **<2.3pg/ml**. This was determined by adding 2 standard deviations to the mean OD obtained when the zero standard was assayed 36 times.

12.2. Specificity

The assay recognizes natural human IL-17A. To define specificity of this ELISA, several proteins were tested for cross reactivity. There was no cross reactivity observed for any protein tested (IL-1 β , IL-6, IL-23, IFN_γ, IL-17B, IL-17B, IL-17F, IL-17A/F and murine IL-17A).

12.3. Precision

Intra-assay

Reproducibility within the assay will be evaluated in three independent experiments. Each assay will be carried out with 6 replicates (3 duplicates) in 2 human pooled serum, 2 in RPMI and 2 in standard diluent with samples containing different concentrations of IL-17A. 2 standard curves were run on each plate **The overall intra-assay coefficient of variation has been calculated to be 3.3%**.

Session	Sample	Mean IL-17A pg/ml	SD	CV
	Sample 1	73.23	1.15	1.6
	Sample 2	36.03	1.34	3.7
Session 1	Sample 3	67.82	2.30	3.4
Session I	Sample 4	31.35	1.18	3.8
	Sample 5	64.30	3.30	5.1
	Sample 6	30.30	1.54	5.1
	Sample 1	67.41	2.57	3.8
	Sample 2	35.88	2.01	5.6
Session 2	Sample 3	62.42	2.59	4.2
Session 2	Sample 4	32.73	0.34	1.0
	Sample 5	60.01	1.44	2.4
	Sample 6	31.83	0.76	2.4
	Sample 1	72.20	2.92	4.1
	Sample 2	34.89	1.67	4.8
Session 3	Sample 3	64.61	1.30	2.0
Session 3	Sample 4	30.45	1.17	3.9
	Sample 5	57.90	0.54	0.9
	Sample 6	30.75	0.88	2.9

Assay to assay reproducibility within one laboratory will be evaluated in three independent experiments by two technicians. Each assay will be carried out with 6 replicates (3 duplicates) in 2 human pooled serum, 2 in RPMI and 2 in standard diluent with samples containing different concentrations of IL-17A. 2 standard curves were run on each plate. **The calculated overall coefficient of variation was 5.2%**.

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6
Mean IL-17A pg/ml	67	34	60	31	60	31
SD	5	2	6	1	2	1
CV	7.0	6.4	9.3	3.6	2.6	2.5

12.4. Dilution Parallelism

Two spiked human serum with different levels of recombinant IL-17A were analysed at three serial two fold dilutions (1:2-1:16) with two replicates each. Recoveries ranged from 69% to 117% with an overall **mean recovery of 95%.**

12.5. Spike Recovery

The spike recovery was evaluated by spiking three concentrations of recombinant IL-17A in human serum in three experiments. Recoveries ranged from 85% to 123% with an overall **mean recovery of 102%**.

12.6. Stability

Storage Stability

Aliquots of spiked serum sample and culture media were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C and the IL-17A level determined after 24h. There was no significant loss of IL-17A at 2-8°C, 30% loss at RT and more than 50% after 24h at 37°C, when spiked in serum. As a result, we would advise that samples are stored at either -20°C or 2-8°C. When IL-17A is spiked in culture media, no significant loss is observed.

Freeze-thaw Stability

Aliquots of spiked serum were stored frozen at –20°C and thawed up to 5 times and IL-17A level was determined. There was no significant loss of IL-17A after 3 cycles and approximately 10% after 5 cycles. When IL-17A is spiked in culture media, no significant loss is observed after 5 cycles of freezing and thawing.

12.7. Expected serum values

A panel of 20 serum coming from apparently healthy blood donors was tested for IL-17A. All were below the detection level <3 pg/ml.

A panel of 20 plasmas coming from apparently healthy blood donors was tested for IL-17A. All were below the detection level and one was slightly positive (3.6pg/ml)

12.8. Standard Calibration

This immunoassay is calibrated against the International Reference Standard NIBSC 01/420 IL-17A. NIBSC 01/420 is quantitated in International Units (IU). 1IU (approximately 100pg) has been showed to be equivalent to 100 pg OriGenelL-17A.

13. Bibliography

F. Y. Cheung P, K. Wong C, W. K. Lam C, Molecular Mechanisms of Cytokine and Chemokine Release from Eosinophils Activated by IL-17A, IL-17F, and IL-23 : Implication for Th17 Lymphocytes-Mediated Allergic Inflammation. J Immunol 2008 ; 180 : 5625–5635.

Kawaguchi M, Adachi M, Oda N, Kokubu F, Shau-Ku Huang, IL-17 cytokine family. J Allergy Clin Immunol 2004 ; 114 : 1265-73

Ouyang W, K. Kolls J, Zheng Y, The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation. Immunity 2008 ; 28 : 454-467.

Shen F, L. Gaffen S, Structure–function relationships in the IL-17 receptor: Implications for signal transduction and therapy. Cytokine 2008 ; 41 : 92–104.

Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y, IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur. J. Immunol. 2007; 37: 2744–2752.

14. OriGenelL-17A ELISA references

Cunin, P. et al., J. Immunol.,2011;186(7): 4175-4182.

Kanda K. et al., Evaluation of serum leaking enzymes and investigation into new biomarkers for exerciseinduced muscle damage. 2014. Eccentric exercise and muscle damage markers 39-54

15. Assay Summary

Total procedure length : 3h45mn Add sample and diluted standard Ţ Incubate 2 hours at room temperature Wash three times T Add 50µl of biotinylated detection antibody 1 Incubate 1 hour at room temperature Ţ Wash three times Ţ Add 100µl of Streptavidin-HRP 1 Incubate 30min at room temperature ↓ Wash three times 1 Add 100 µl of ready-to-use TMB Protect from light. Let the color develop for 5-15 mn. ↓ Add 100 H₂SO₄

 \downarrow

Read Absorbance at 450 nm

TECHNICAL CONSULTATION

OriGene Technologies, Inc. 9620 Medical Center Dr., Suite 200 Rockville, MD 20850

Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com

For Research Use Only Not for use in diagnostic procedures